OBE 022

Drug Profile

OBE 022

Alternative Names: OBE-022

Latest Information Update: 31 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Serono
  • Developer Merck Serono; ObsEva
  • Class Small molecules; Tocolytics
  • Mechanism of Action Prostaglandin F2 alpha antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Preterm labour

Most Recent Events

  • 15 Aug 2017 ObsEva plans phase IIa PROLONG trial for Preterm labour in fourth quarter of 2017
  • 18 May 2017 Adverse events data from a phase I trial in drug-drug interaction released by ObsEva
  • 18 May 2017 ObsEva completes a phase I trial in drug-drug interaction in healthy women in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top